Search research articles
Contact Us
Filters
Showing results (131-140 of 222) with videos related to
Page
of 23
Sort By:
Molecular Cancer Therapeutics
|
October 15, 2008
Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines
Philip L Lorenzi, Jenny Llamas, Michele Gunsior, et al.
Cancer Chemotherapy and Pharmacology
|
August 4, 2019
A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24
Mansoor Raza Mirza, Troels K Bergmann, Morten Mau-Sørensen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 2006
Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination
Analisa DiFeo, Goutham Narla, Jennifer Hirshfeld, et al.
Cancers
|
April 30, 2021
SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment
Ying Zhu, Sammy Ferri-Borgogno, Jianting Sheng, et al.
Gynecologic Oncology
|
March 27, 2016
Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study
Andrea P Myers, Virginia L Filiaci, Yuping Zhang, et al.
Journal of the American Chemical Society
|
February 7, 2017
Maximizing Synergistic Activity When Combining RNAi and Platinum-Based Anticancer Agents
Haihua Xiao, Ruogu Qi, Ting Li, et al.
The Journal of Clinical Investigation
|
December 19, 2017
Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance
Cecilia S Leung, Tsz-Lun Yeung, Kay-Pong Yip, et al.
Gynecologic Oncology
|
February 22, 2020
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
David M O'Malley, Ursula A Matulonis, Michael J Birrer, et al.
Biomaterials
|
May 9, 2017
Early tumor detection afforded by in vivo imaging of near-infrared II fluorescence
Zhimin Tao, Xiangnan Dang, Xing Huang, et al.
The New England Journal of Medicine
|
December 30, 2011
Incorporation of bevacizumab in the primary treatment of ovarian cancer
Robert A Burger, Mark F Brady, Michael A Bookman, et al.
Page
of 23
Search research articles
Search
Showing results (131-140 of 222) with videos related to
Sort By:
Page
of 23
Molecular Cancer Therapeutics
|
October 15, 2008
Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines
Philip L Lorenzi, Jenny Llamas, Michele Gunsior, et al.
Cancer Chemotherapy and Pharmacology
|
August 4, 2019
A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24
Mansoor Raza Mirza, Troels K Bergmann, Morten Mau-Sørensen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 2006
Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination
Analisa DiFeo, Goutham Narla, Jennifer Hirshfeld, et al.
Cancers
|
April 30, 2021
SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment
Ying Zhu, Sammy Ferri-Borgogno, Jianting Sheng, et al.
Gynecologic Oncology
|
March 27, 2016
Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study
Andrea P Myers, Virginia L Filiaci, Yuping Zhang, et al.
Journal of the American Chemical Society
|
February 7, 2017
Maximizing Synergistic Activity When Combining RNAi and Platinum-Based Anticancer Agents
Haihua Xiao, Ruogu Qi, Ting Li, et al.
The Journal of Clinical Investigation
|
December 19, 2017
Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance
Cecilia S Leung, Tsz-Lun Yeung, Kay-Pong Yip, et al.
Gynecologic Oncology
|
February 22, 2020
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
David M O'Malley, Ursula A Matulonis, Michael J Birrer, et al.
Biomaterials
|
May 9, 2017
Early tumor detection afforded by in vivo imaging of near-infrared II fluorescence
Zhimin Tao, Xiangnan Dang, Xing Huang, et al.
The New England Journal of Medicine
|
December 30, 2011
Incorporation of bevacizumab in the primary treatment of ovarian cancer
Robert A Burger, Mark F Brady, Michael A Bookman, et al.
Page
of 23